Is Royalty Pharma (RPRX) a buy or sell?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Royalty Pharma stock is Buy based on the current 1 hold rating and 2 buy ratings for RPRX. The average twelve-month price target for Royalty Pharma is $48.67 with a high price target of $50.00 and a low price target of $46.00. Learn more
What is the price target for Royalty Pharma stock?
The average twelve-month price target for Royalty Pharma is $48.67 with a high price target of $50.00 and a low price target of $46.00. Learn more Do Wall Street analysts like Royalty Pharma more than its competitors? Analysts like Royalty Pharma stock more than the stock of other Finance companies.
Do analysts agree on Royalty Pharma's (Ryp) price targets?
The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $48.67, Royalty Pharma has a forecasted upside of 20.6% from its current price of $40.34.
Is there an upside for Royalty Pharma (RPH)?
According to analysts' consensus price target of $48.67, Royalty Pharma has a forecasted upside of 20.6% from its current price of $40.34. Royalty Pharma has received no research coverage in the past 90 days. Royalty Pharma has received 293 “outperform” votes. (Add your “outperform” vote.) Royalty Pharma has received 132 “underperform” votes.
When will Royalty Pharma release its earnings?
What is the NASDAQ symbol for Royalty Pharma?
How much does Royalty Pharma make?
How much dividend does Royalty Pharma pay?
What is the dividend payout ratio for Royalty Pharma?
What is Royalty Pharma?
How much of Royalty Pharma stock is owned by insiders?
See more
About this website
Should I buy or sell Royalty Pharma stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 6 buy rating...
What is Royalty Pharma's stock price forecast for 2022?
6 equities research analysts have issued 12 month price objectives for Royalty Pharma's shares. Their forecasts range from $48.00 to $56.00. On ave...
How has Royalty Pharma's stock performed in 2022?
Royalty Pharma's stock was trading at $39.85 at the beginning of the year. Since then, RPRX shares have increased by 1.6% and is now trading at $40...
When is Royalty Pharma's next earnings date?
Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Roy...
How were Royalty Pharma's earnings last quarter?
Royalty Pharma plc (NASDAQ:RPRX) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported $0.61 earnings...
How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?
Royalty Pharma declared a quarterly dividend on Tuesday, April 19th. Shareholders of record on Friday, May 20th will be paid a dividend of $0.19 pe...
Is Royalty Pharma a good dividend stock?
Royalty Pharma(NASDAQ:RPRX) pays an annual dividend of $0.76 per share and currently has a dividend yield of 1.85%. Royalty Pharma has been increas...
Who are Royalty Pharma's key executives?
Royalty Pharma's management team includes the following people: Mr. Pablo Gerardo Legorreta , Founder, Chairman & CEO (Age 57, Pay $49.51M) Mr....
Who are some of Royalty Pharma's key competitors?
Some companies that are related to Royalty Pharma include Johnson & Johnson (JNJ) , Eli Lilly and (LLY) , Pfizer (PFE) , AbbVie (ABBV) , Merck...
Royalty Pharma Price Target, Predictions & Analyst Ratings
The current Royalty Pharma (NASDAQ:RPRX) price target is $51.57. Learn why top analysts are making this price prediction at MarketBeat.
Research Reports & Trade Ideas - Yahoo Finance
View research reports from Argus and trade ideas from Trading Central to understand future stock performances and find high performing trade ideas.
Royalty Pharma plc (RPRX) Latest Stock News & Headlines - Yahoo Finance
Get the latest Royalty Pharma plc (RPRX) stock news and headlines to help you in your trading and investing decisions.
Royalty Pharma PLC (RPRX) Stock Price, Quote & News | Stock Analysis
Analyst Forecast. According to 16 analysts, the average rating for RPRX stock is "Buy." The 12-month stock price forecast is 53.49, which is an increase of 21.76% from the latest price.
Royalty Pharma plc (RPRX) Stock Price Today, Quote & News
A high-level overview of Royalty Pharma plc (RPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Royalty Pharma plc - RPRX - Stock Price & News | The Motley Fool
Real time Royalty Pharma plc (RPRX) stock price quote, stock graph, news & analysis.
About the company
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to gl obal pharmaceutical companies.
Explore our tools
All content on FT.com is for your general information and use only and is not intended to address your particular requirements.
How much does Royalty Pharma make?
Royalty Pharma has a market capitalization of $24.48 billion and generates $2.12 billion in revenue each year. The biopharmaceutical company earns $975.04 million in net income (profit) each year or $1.61 on an earnings per share basis.
How much dividend does Royalty Pharma pay?
Royalty Pharma pays an annual dividend of $0.68 per share and currently has a dividend yield of 1.68% . Royalty Pharma does not yet have a strong track record of dividend growth. The dividend payout ratio of Royalty Pharma is 42.24%. This payout ratio is at a healthy, sustainable level, below 75%.
What is the dividend payout ratio for Royalty Pharma?
Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 21.59% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. View Royalty Pharma's dividend history.
What is Royalty Pharma?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
How much of Royalty Pharma stock is owned by insiders?
25.86% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
What is the NASDAQ symbol for Royalty Pharma?
Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."
What is the P/E ratio of Royalty Pharma?
The P/E ratio of Royalty Pharma is 32.22, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 13.23.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
RPRX's average price target has moved down $0.29 over the prior 19 months.
The Trend in the Broker Recommendations
Over the past 61 days, RPRX's average broker recommendation rating improved by 0.
What is Royalty Pharma?
Royalty Pharma plc is a biopharmaceutical royalty purchaser and innovation sponsor for the US biopharmaceutical industry. He is also involved in identifying, evaluating and obtaining royalties for various biopharmaceuticals. In addition, the company partners with innovators from academic institutions, research hospitals and non-profit organizations, small and medium-sized biotech companies, and pharmaceutical companies.
How to calculate market capitalization?
It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
What is trailing P/E?
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Analyst price target for RPRX
Based on 3 analyst s offering 12 month price targets for Royalty Pharma plc.
RPRX earnings per share forecast
What is RPRX 's earnings per share in the next 3 years based on estimates from 5 analyst s?
RPRX revenue forecast
What is RPRX 's revenue in the next 3 years based on estimates from 3 analyst s?
RPRX earnings growth forecast
How is RPRX forecast to perform vs Biotechnology companies and vs the US market?
RPRX revenue growth forecast
How is RPRX forecast to perform vs Biotechnology companies and vs the US market?
How much is the dividend for RPRX 2021?
NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.
When will Royalty Pharma report results?
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information The conference call can be accessed live over the phone by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 5652058. A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) [email protected]
What is the Vickers top buyer and seller?
Daily – Vickers Top Buyers & Sellers for 10/04/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What is the reason for the increase in the first quarter of 2021?
The increase in the first quarter of 2021 resulted from higher cash collections from financial royalty assets, primarily from the cystic fibrosis franchise, Imbruvica and new assets acquired subsequent to the first quarter of 2020.
How long is a conference call replay archived?
A replay of the conference call and webcast will be archived on the company's website for at least 30 days. To ask a question during the live broadcast or listen without internet access, please dial in at least 15 minutes in advance to ensure a timely connection to the call.
When will Royalty Pharma pay dividends?
The dividend will be paid on June 15, 2021, to shareholders of record at the close of business on May 20, 2021. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com Royalty Pharma Investor Relations and Communications +1 (212) [email protected]
Who bought Oxlumo in 2021?
Summary of Recent Royalty Acquisition Activity Oxlumo: In April 2021, Royalty Pharma announced that it acquired a royalty interest in Oxlumo (lumasiran) from Dicerna Pharmaceuticals for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.
When will Royalty Pharma release its earnings?
Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021. View our earnings forecast for Royalty Pharma.
What is the NASDAQ symbol for Royalty Pharma?
Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."
How much does Royalty Pharma make?
Royalty Pharma has a market capitalization of $24.48 billion and generates $2.12 billion in revenue each year. The biopharmaceutical company earns $975.04 million in net income (profit) each year or $1.61 on an earnings per share basis.
How much dividend does Royalty Pharma pay?
Royalty Pharma pays an annual dividend of $0.68 per share and currently has a dividend yield of 1.68% . Royalty Pharma does not yet have a strong track record of dividend growth. The dividend payout ratio of Royalty Pharma is 42.24%. This payout ratio is at a healthy, sustainable level, below 75%.
What is the dividend payout ratio for Royalty Pharma?
Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 21.59% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. View Royalty Pharma's dividend history.
What is Royalty Pharma?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
How much of Royalty Pharma stock is owned by insiders?
25.86% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
